Innovations In Clinical Neuroscience

JAN-FEB 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/796206

Contents of this Issue

Navigation

Page 58 of 63

[ V O L U M E 1 4 , N U M B E R 1 – 2 , J A N U A R Y – F E B R U A R Y 2 0 1 7 ] Innovations in CLINICAL NEUROSCIENCE 59 1992;4(2):145–151. 7. Urban-Kowalczyk M, Rudecki T, Wroblewski D, et al. Electroconvulsive therapy in patient with psychotic depression and multiple sclerosis. Neurocase. 2014;20(4):452–455. 8. Pontikes TK, Dinwiddie SH. Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia. J ECT. 2010;26(4):270–271. 9. Serafini G, Howland RH, Rovedi F, et al. The role of ketamine in treatment- resistant depression: a systematic review. Curr Neuropharmacol. 2014;12(5):444–461. 10. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N- methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. 11. Messer M, Haller IV. Maintenance ketamine treatment produces long- term recovery from depression. Primary Psychiatry. 2010;17(4):54–56. 12. Messer M, Haller IV, Larson P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci. 2010;22(4):442–444. 13. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003;1003:250–272. 14. Zarate CA, Jr., Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003;1003:273–291. 15. Zarate CA, Manji HK. Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol. 2008;4(9):1223–1234. 16. Sakai T, Tomiyasu S, Ono T, et al. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain. 2004;20(5):375–376. 17. Sakai T, Ichiyama T, Whitten CW, et al. Ketamine suppresses endotoxin- induced NF-kappaB expression. Can J Anaesth. 2000;47(10):1019–1024.

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2017